Buradasınız

Anasayfa » Content

Kronik Miyeloid Lösemide İmatinib Tedavisi

Imatinib Therapy in Chronic Myeloid Leukemia

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Imatinib mesylate is an inhibitor of the BCR-ABL tyrosine kinase, the putative cause of chronic myelogenous leukemia (CML). It was observed in clinical trials that as a targeted therapy, it has demonstrated high levels of efficacy both clinically and cytogenetically. In this study ten patients with chronic phase CML diagnosis that were treated with imatinib therapy in our hematology department were evaluated retrospectively. It was established that all the patients tolerated the drug well and most of the unresponsive patients to previous therapy achieved hematologic and cytogenetic response. In conclusion, although the long term follow-up results are not available, imatinib seems to be a well tolerated and efficient therapy for CML patients.
Bookmark/Search this post with
Abstract (Original Language): 
İmatinib mesilat, kronik miyeloid löseminin (KML) etkeni olduğu ifade edilen BCR-ABL tirozin kinazın inhibitörüdür. Klinik çalışmalarda, hedefe yönelik tedavi olarak, yüksek düzeyde klinik ve sitogenetik etkinlik gösterdiği gözlenmiştir. Bu çalışmada Hematoloji Bilim Dalında imatinib ile tedavi edilen on kronik faz KML’li olgu retrospektif olarak değerlendirildi. Tüm hastaların tedaviyi iyi tolere ettiği ve önceki tedaviye yanıtsız hastalarda hematolojik ve sitogenetik cevabın oluştuğu tespit edildi. Sonuç olarak, uzun dönemli takip verileri henüz olmamasına rağmen KML’li hastalarda imatinib iyi tolere edilen ve etkin bir tedavi yöntemi gibi görünmektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-kronik-miyeloid-losemide-imatinib-tedavisi.pdf
  • 2
63-66
  • Turkish

REFERENCES

References: 

1. Mughal TI, Goldman JM. Chronic myeloid leukemia: STI 571
magnifies the therapeutic dilemma. Eur J Cancer
2001;37:561-68.
2. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R,
Kantarjian HM. The biology of chronic myeloid leukemia. N
Engl J Med1999;341:164-71.
3. John AM, Thomas NSB, Mufti GJ, Padua RA. Targeted
therapies in myeloid leukemia. Semin Cancer Biol
2004;14:41-62.
4. O’Dwyer ME, Mauro MJ, Druker BJ. STI571 as a targeted
therapy for CML. Cancer Invest 2003;21:429-38.
5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford
JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S,
Sawyers CL. Efficacy and safety of a specific inhibitor of the
bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J
Med 2001; 344:1031-37.
6. Cervantes F, Hernández-Boluda JC, Steegmann JL, Conde E,
Alvarez–Larrán A, López-Jiménez J, Osorio S, Villalón L,
Camós M, Garcia-Conde J, Odriozola J. Imatinib mesylate
therapy of chronic phase chronic myeloid leukemia resistant
or intolerant to interferon: results and prognostic factors for
response and progression–free survival in 150 patients.
Hematologica 2003;88:1117-22.
7. Goldman JM. Chronic myeloid leukemia- still a few
questions. Exp Hematol 2004;32:2-10.
8. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani
M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A,
Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J,
Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman
JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE,
Capdeville R, Druker BJ. Imatinib compared with interferon
and low-dose cytarabine for newly diagnosed chronic phase
chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
9. Kantarjian HM, O’Brien S, Cortes J, Giles FJ, Rios MB, Shan
J, Faderi S, Garcia-Manero G, Ferrajoli A, Verstovsek S,
Wierda W, Keating M, Talpaz M. Imatinib mesylate therapy
improves survival in patients with newly diagnosed
Philadelphia chromosome-positive chronic myelogenous
leukemia in the chronic phase. Cancer 2003;98:2636-42.
10. Goldman JM, Marin D, Olavarria E, Apperley JF. Clinical
decisions for chronic myeloid leukemia in the imatinib era.
Semin Hematol 2003;40:98-103.
11. Ross DM, Hughes TP. Cancer treatment with kinase
inhibitors: what have we learnt from imatinib? Br J Cancer
2004;90:12-9.
12. Sacha T, Hochhaus A, Hanfstein B, Müller MC, Rudzki Z,
Czopek J, Wolska-Smolen T, Czekalska S, Salamanchuk Z,
Jakóbczyk M, Skotnicki AB. ABL–kinase domain point
mutation as a cause of imatinib (STI571) resistance in CML
patient who progress to myeloid blast crisis. Leuk Res
2003;27:1163-66.
13. Rothberg PG. Imatinib: resisting the resistance. Leuk Res
2003;27:977-8.
14. Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M,
Müller C, Niederwieser D, Druker BJ, Werner M, Deininger
N. High incidence of BCR-ABL kinase domain mutations and
absence of mutations of the PDGFR and KIT activation loops
in CML patients with secondary resistance to imatinib.
Hematol J 2004;5:55-60.
15. Kantarjian HM, Talpaz M, O’Brien S, Giles F, Garcia-Manero
G, Faderl S, Thomas D, Shan J, Rios MB, Cortes J. Dose
escalation of imatinib mesylate can overcome resistance to
standard-dose therapy in patients with chronic myeloid
leukemia. Blood 2003;101:473-5.
16. Schwarz M, Kreuzer KA, Baskaynak G, Dorken B, Le Coutre
P. Imatinib-induced acute generalized exanthematous
pustulosis (AGEP) in two patients with chronic myeloid
leukemia. Eur J Haematol 2002;69:254-6.
17. Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA,
Kantarjian HM, Talpaz M. Severe periorbital edema
secondary to STI571 (Gleevec). Cancer 2002;95:881-7.
18. Özçelik T, Özkalemkaş F, Ali R, Özkocaman V, Ozan Ü,
Tunalı A. Unusually prolonged myelosuppression due to
Gleevec treatment. Haema 2004;7:114-5.
19. Ali R, Özkalemkaş F, Özkocaman V, Özçelik T, Ozan Ü,
Kimya Y, Tunalı A. Successful pregnancy and delivery in a
patient with chronic myelogenous leukemia (CML), and
management of CML with leukapheresis during pregnancy: a
case report and review of the literature. Jpn J Clin Oncol
2004;34:215-7.

Thank you for copying data from http://www.arastirmax.com